An Z - Search Results

1

Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.

Anami Y, Xiong W, Gui X, Deng M, Zhang CC, Zhang N, An Z, Tsuchikama K. Anami Y, et al. Among authors: an z. Org Biomol Chem. 2017 Jul 5;15(26):5635-5642. doi: 10.1039/c7ob01027c. Org Biomol Chem. 2017. PMID: 28649690

2

A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.

Fan X, Brezski RJ, Fa M, Deng H, Oberholtzer A, Gonzalez A, Dubinsky WP, Strohl WR, Jordan RE, Zhang N, An Z. Fan X, et al. Among authors: an z. Breast Cancer Res. 2012 Aug 8;14(4):R116. doi: 10.1186/bcr3240. Breast Cancer Res. 2012. PMID: 22873525 Free PMC article.

3

HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways.

Choi BK, Cai X, Yuan B, Huang Z, Fan X, Deng H, Zhang N, An Z. Choi BK, et al. Among authors: an z. Protein Cell. 2012 Oct;3(10):781-9. doi: 10.1007/s13238-012-2065-y. Epub 2012 Sep 15. Protein Cell. 2012. PMID: 22983903 Free PMC article.

4

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.

Choi BK, Fan X, Deng H, Zhang N, An Z. Choi BK, et al. Among authors: an z. Cancer Med. 2012 Aug;1(1):28-38. doi: 10.1002/cam4.10. Epub 2012 Jul 15. Cancer Med. 2012. PMID: 23342251 Free PMC article.

5

Human decellularized adipose tissue scaffold as a model for breast cancer cell growth and drug treatments.

Dunne LW, Huang Z, Meng W, Fan X, Zhang N, Zhang Q, An Z. Dunne LW, et al. Among authors: an z. Biomaterials. 2014 Jun;35(18):4940-9. doi: 10.1016/j.biomaterials.2014.03.003. Epub 2014 Mar 21. Biomaterials. 2014. PMID: 24661550

6

The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling.

Huang Z, Choi BK, Mujoo K, Fan X, Fa M, Mukherjee S, Owiti N, Zhang N, An Z. Huang Z, et al. Among authors: an z. Oncogene. 2015 Feb 26;34(9):1105-15. doi: 10.1038/onc.2014.56. Epub 2014 Mar 24. Oncogene. 2015. PMID: 24662824

7

Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation.

Shi Y, Fan X, Meng W, Deng H, Zhang N, An Z. Shi Y, et al. Among authors: an z. Breast Cancer Res. 2014 Apr 2;16(2):R33. doi: 10.1186/bcr3637. Breast Cancer Res. 2014. PMID: 24693969 Free PMC article.

8

Regulation of ERBB3/HER3 signaling in cancer.

Mujoo K, Choi BK, Huang Z, Zhang N, An Z. Mujoo K, et al. Among authors: an z. Oncotarget. 2014 Nov 15;5(21):10222-36. doi: 10.18632/oncotarget.2655. Oncotarget. 2014. PMID: 25400118 Free PMC article. Review.

9

Aberrant RSPO3-LGR4 signaling in Keap1-deficient lung adenocarcinomas promotes tumor aggressiveness.

Gong X, Yi J, Carmon KS, Crumbley CA, Xiong W, Thomas A, Fan X, Guo S, An Z, Chang JT, Liu QJ. Gong X, et al. Among authors: an z. Oncogene. 2015 Sep 3;34(36):4692-701. doi: 10.1038/onc.2014.417. Epub 2014 Dec 22. Oncogene. 2015. PMID: 25531322 Free PMC article.

10

A novel therapeutic strategy to rescue the immune effector function of proteolytically inactivated cancer therapeutic antibodies.

Fan X, Brezski RJ, Deng H, Dhupkar PM, Shi Y, Gonzalez A, Zhang S, Rycyzyn M, Strohl WR, Jordan RE, Zhang N, An Z. Fan X, et al. Among authors: an z. Mol Cancer Ther. 2015 Mar;14(3):681-91. doi: 10.1158/1535-7163.MCT-14-0715. Epub 2014 Dec 31. Mol Cancer Ther. 2015. PMID: 25552368

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,201 results

Search Page

Filters